PT-141 is one of the few peptides in the gray market with an FDA approval behind it, and that is exactly why it confuses people. US search interest in it has roughly doubled over the past year, peaking in the last week of August, and it now draws more searches than SS-31, epitalon or DSIP. The approval is real. It is also for premenopausal women with a diagnosed desire disorder, and the label says in plain words that it is not for men and not for enhancing sexual performance. Almost everyone buying a vial of "PT-141" is a man looking for exactly that.
So what is it, what did the trials actually measure, what happened to the men's program, and why did the FDA name it in four warning letters on August 24? Let's dive in.
TLDR
What is PT-141? Bremelanotide, a small cyclic peptide that switches on melanocortin-4 receptors in the brain. It works on desire, not on blood flow, which is what separates it from Viagra and Cialis. It is sold as Vyleesi, a single-dose autoinjector.
Results: In two Phase 3 trials of 1,267 premenopausal women, as-needed 1.75 mg raised a desire score by 0.35 points more than placebo on a scale that runs from 1.2 to 6. Real, reproduced, and small. In men, early nasal-spray trials produced erections, but that program never reached approval.
Dosage: The approved dose is 1.75 mg under the skin at least 45 minutes before sex, no more than once in 24 hours and no more than eight times a month. No trial has tested injected bremelanotide in men. Online protocols for men quote doses with no source behind them.
Safety: Nausea in 40% of women in the trials. Every dose briefly raises blood pressure. Patches of darkened skin in 1%, which did not always fade. Contraindicated with uncontrolled high blood pressure or heart disease.
Legal Status (October 2026): FDA-approved as Vyleesi for one indication. Lawful off-label by prescription. Research-labelled vials are unapproved drugs in the FDA's view, and four sellers were told so in writing on August 24, 2026. Not named on the WADA Prohibited List.
What Is PT-141, and Why Is Everyone Searching for It Now?
PT-141 started life as a side effect. Melanotan II was a tanning peptide developed in the 1990s, and the surprise in its early trials was spontaneous erections. Bremelanotide is melanotan II with one small change at the end of the chain, which keeps most of the sexual effect and loses most of the tanning (Pfaus et al., 2022, CNS Spectrums, PMID 33455598).
Palatin Technologies developed it, first as a nasal spray for men, then as an injection for women. The FDA approved it as Vyleesi on June 21, 2019, and Cosette Pharmaceuticals has held the product since 2023.
The search spike comes down to two things landing on top of each other. The men's-health telehealth market has been selling compounded PT-141, often as a nasal spray, as the next step after Viagra and Cialis. And on August 24, 2026, the FDA posted warning letters to four online peptide sellers, Tex Peptides, Royal Peptides, Peptide Partners and NuScience Peptides, each of which listed PT-141 among the products the agency called unapproved new drugs. The top related searches tell you what people want to know: "pt 141 for men," "pt 141 for women," "pt 141 nasal spray," "pt 141 dosage."
PT-141 is not an experimental peptide waiting for approval. It is an approved drug being sold to the one group its label was written to exclude.
How Does PT-141 Work?
Here's the part most people get wrong. PT-141 does nothing to blood vessels. Sildenafil and tadalafil work by relaxing the blood vessels of the penis, so they need arousal to already be there. Bremelanotide works upstream, in the brain.
It activates melanocortin-4 (MC4) receptors in the hypothalamus. Those receptors sit in the circuitry that balances dopamine-driven excitation against serotonin-driven inhibition, and tipping that balance toward excitation is what increases desire (Pfaus et al., 2022, CNS Spectrums, PMID 33455598).
That central action explains three things at once. It is why it was tested for low desire in women. It is why the early men's trials saw erections without any sexual stimulation. And it is why its side effects, nausea, flushing and a blood pressure bump, show up across the whole body rather than at the injection site.
It is also short-acting. After an injection, its half-life is about 2.7 hours, which is why it is dosed per occasion rather than daily (Vyleesi prescribing information, 2024).
PT-141 vs Flibanserin vs Sildenafil vs Melanotan II
| Compound | How it works | Approved for | How it is taken | The catch |
|---|---|---|---|---|
| PT-141 (Vyleesi) | Brain: MC4 receptor agonist | Low desire (HSDD) in premenopausal women | 1.75 mg injection, as needed, max 8 per month | Nausea in 40%; blood pressure rises after each dose; not indicated in men |
| Flibanserin (Addyi) | Brain: serotonin receptors | Low desire (HSDD) in premenopausal women | 100 mg tablet every night at bedtime | Boxed warning for fainting and low blood pressure, especially with alcohol; not indicated in men |
| Sildenafil / tadalafil | Blood vessels: PDE5 inhibitor | Erectile dysfunction in men | Tablet before sex, or daily for tadalafil | Needs arousal to work; does nothing for desire |
| Melanotan II | Melanocortin receptors, broadly | Nothing, anywhere | Gray-market injection | FDA lists melanoma, priapism and brain swelling case reports |
Here's the caveat that gets dropped in almost every comparison: no trial has ever compared PT-141 head-to-head with sildenafil or tadalafil in men. The only men's trial built around those drugs tested PT-141 in men they had already failed, and that trial now carries a journal warning (more on that below).
The comparison that does exist is with flibanserin, the other desire drug for women. They are not alternatives so much as opposites in how they are used: flibanserin is a pill every night with an alcohol warning, PT-141 is an injection only when needed.
What the Evidence Actually Shows
Published: the approval trials in women
RECONNECT was two identical 24-week, randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized hypoactive sexual desire disorder. Of 1,267 women randomized, nearly all were treated at US sites, with a mean age of 39 (Kingsberg et al., 2019, Obstetrics and Gynecology, PMID 31599840).
The women injected 1.75 mg as needed. Desire scores rose by 0.30 and 0.42 points more than placebo in the two studies, 0.35 when the two were combined. Distress about low desire fell by 0.33 points more than placebo combined. Every one of those differences was statistically significant.
Now the context. The desire scale runs from 1.2 to 6. A 0.35-point advantage over placebo is real and it held up in two separate trials, but it is small, and the placebo groups improved too. Whether that is clinically meaningful was argued about at approval and is still a judgement call. Pre-planned subgroup analyses found the effect broadly consistent across age, weight and prior treatment (Simon et al., 2022, Journal of Women's Health, PMID 35230162).
Published: the men's trials
This is where most of the online hype comes from, and the evidence is thinner than it sounds.
In 2004, intranasal PT-141 produced significant erectile responses in healthy men without visual stimulation, and in men with mild-to-moderate erectile dysfunction with it, at doses above 7 mg, with onset around 30 minutes (Diamond et al., 2004, International Journal of Impotence Research, PMID 14963471). That was an early safety and dose-finding study, not an efficacy trial.
In 2008, a trial in 342 men who had not responded to sildenafil reported positive responses in 33.5% on 10 mg intranasal bremelanotide against 8.5% on placebo (Safarinejad and Hosseini, 2008, Journal of Urology, PMID 18206919). Here's the part that rarely gets mentioned: in January 2023 the Journal of Urology published an expression of concern about that paper (PMID 36626345). It has not been retracted, but the journal has formally flagged it, and it is the single largest men's trial anyone cites.
The men's evidence is two nasal-spray studies, at doses that don't match anything sold, and the bigger one carries a journal warning. No trial has tested injected PT-141 in men.
Evidence status at a glance
| Question | What exists | Status |
|---|---|---|
| Desire in premenopausal women with HSDD | Two Phase 3 trials, 1,267 women, 24 weeks | Published; basis of FDA approval |
| Erections in men (intranasal) | 2004 dose-finding study; 2008 trial in sildenafil non-responders | Published; 2008 trial under expression of concern |
| Injected PT-141 in men | None | No trial registered |
| Postmenopausal women | None supporting use | Label says not indicated |
| "Libido enhancement" without a diagnosis | None | Label says not indicated to enhance sexual performance |
| Safety beyond 24 weeks | None published | Unknown |
Dosage: What the Label Says vs What the Community Runs
Let's get this straight first: the only validated dosing protocol for PT-141 is the one on the Vyleesi label, and it was validated in women. There is no validated protocol for men, for injection or nasal spray.
The approved dose
1.75 mg injected under the skin of the abdomen or thigh, at least 45 minutes before anticipated sex. No more than one dose in 24 hours. More than eight doses a month is not recommended. If there is no improvement after eight weeks, the label says to stop (Vyleesi prescribing information, 2024).
Those limits aren't arbitrary. They sit alongside a blood pressure rise after every dose and skin darkening that was more common with daily dosing. The autoinjector enforces them physically: it holds one dose and nothing else.
What the community runs
Online protocols for men most often quote 1 to 2 mg per use by injection, with 2 mg presented as a ceiling. We could not find a primary source for any of those numbers. They circulate on vendor and forum pages without a trial behind them, so treat them as folklore, not data.
Nasal sprays sold by telehealth clinics are compounded products. The nasal route is the one the old men's trials used, but at doses of 7 mg and up, through a different route with different absorption, so the numbers do not map onto a 1.75 mg injection.
The reconstitution math
Research vials are usually 10 mg of powder. That is five full 1.75 mg doses with a little left over. Here is how the volume of bacteriostatic water changes what you draw on a standard U-100 insulin syringe (100 units = 1 mL):
| BAC water added to 10 mg | Concentration | Units for 1 mg | Units for 1.75 mg |
|---|---|---|---|
| 1 mL | 10 mg/mL | 10 units | 17.5 units |
| 2 mL | 5 mg/mL | 20 units | 35 units |
| 3 mL | 3.33 mg/mL | 30 units | 52.5 units |
More water means bigger, easier-to-measure volumes. At 1 mL, a 1.75 mg dose sits between two tick marks and is easy to get wrong. Run your own numbers with the reconstitution calculator and the dosage calculator.
One more practical point. The FDA's general guidance for multi-dose vials is to discard them 28 days after first use. At the label's ceiling of eight doses a month, a 10 mg vial runs out first. At the once-a-week use most people describe, it doesn't, and the rest goes in the bin.
Side Effects
Nausea. The big one. 40% of women in the trials, 13% needed anti-nausea medication, and 8% quit because of it. For most it improved with the second dose (Vyleesi prescribing information, 2024).
Blood pressure and heart rate. Every dose raises blood pressure, by up to 6 mmHg systolic and 3 mmHg diastolic, peaking two to four hours after the injection, while heart rate drops by up to 5 beats per minute. Both usually return to baseline within 12 hours. That is why the drug is contraindicated in uncontrolled hypertension and known heart disease, and not recommended for anyone at high cardiovascular risk.
Skin darkening. Focal hyperpigmentation of the face, gums or breasts in 1% of women at up to eight doses a month. The risk was higher with darker skin and with daily dosing, and the label notes that it did not always clear up after stopping.
The rest. Flushing, headache, injection site reactions and vomiting all showed up in more than 4% of trial participants.
Drug interactions. It slows stomach emptying, which can affect oral medications, and it sharply lowers blood levels of oral naltrexone. The label says to avoid it in anyone taking naltrexone for alcohol or opioid dependence.
The gray-market risk is its own problem
Every number above belongs to 1.75 mg, at most eight times a month, in women whose blood pressure was checked first. Community use by men tends to run more often and at higher doses, with no blood pressure check at all.
Then there is the vial itself. Research vendors who sell PT-141 often sell melanotan II right alongside it, and the two molecules differ by a single dalton of mass. The FDA's compounding list says published case reports on melanotan II "discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism." A purity certificate can't tell the two apart unless it reports the observed mass precisely. Our PT-141 sourcing page covers what to look for.
Stop and get checked if you notice an erection lasting more than four hours, a pounding headache or racing pulse after a dose, new darkening of the skin, or new or changing moles.
The Legal and Regulatory Situation
The approved product. Vyleesi is a prescription drug in the US for premenopausal women with acquired, generalized HSDD. It has not been approved in the EU, and we are not aware of an approval anywhere else.
Off-label prescribing. A doctor can lawfully prescribe it to a man off-label. That doesn't create evidence for the use, and it doesn't switch off the label's cardiovascular warnings.
Compounding. Because bremelanotide is the active ingredient in an approved drug, a 503A pharmacy can compound it without it being on the bulks list, but not as "essentially a copy" of Vyleesi. The FDA's guidance treats a compounded product with the same ingredient, a similar strength and the same route as a copy unless a prescriber documents a patient-specific reason, and it says explicitly that a lower price is not a reason (FDA, 2018). For men, there is no approved product to copy, so a compounded nasal spray or vial is off-label prescribing of a compounded drug whose label excludes them.
Research-use-only vials. On August 24, 2026, the FDA posted warning letters to Tex Peptides, Royal Peptides, Peptide Partners and NuScience Peptides. Each letter, based on a review of the seller's website in July 2026, named PT-141 among products the agency called unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act, alongside retatrutide, tesamorelin, SS-31 and others. Three of the four letters also named the bacteriostatic water the sellers offered for reconstitution. The letters warn that failing to fix the violations may lead to seizure and injunction without further notice.
A "research use only" label doesn't protect a product the seller describes in terms of desire and arousal. The FDA quoted those product pages back to the sellers.
Sport. Bremelanotide is not named on the WADA Prohibited List.
For how the FDA treats the peptides that are not approved at all, see our July 2026 FDA committee rundown.
The Honest Take
PT-141 is a legitimate drug with a modest, reproducible effect on desire in one group of women, a real blood pressure effect, and a nausea rate that makes plenty of people stop. That is what the approval actually says.
For men, the honest picture is much thinner than the marketing. The early nasal-spray studies were promising, the biggest of them is now under a journal's expression of concern, and nobody has ever tested the injection in men. Every "PT-141 for men" protocol online is extrapolating from a women's approval and a men's program that was abandoned.
If you have erectile dysfunction and haven't tried the approved, cheap, generic options, start there. If you have and they failed, PT-141 is a reasonable thing to discuss with a doctor who will check your blood pressure first. A vial from a site that also sells tanning peptides is a different proposition entirely: you don't know the dose, you don't know the molecule, and you are skipping the one safety check the label requires.
The approval is real. It just belongs to someone else.
FAQ
What is PT-141?
PT-141 is bremelanotide, a peptide that acts on melanocortin-4 receptors in the brain to increase sexual desire. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder.
Does PT-141 work for men?
Early intranasal trials showed erectile responses in men, but the program was never approved, the largest trial carries a 2023 expression of concern, and injected PT-141 has never been tested in men.
Does PT-141 work for women?
In premenopausal women with diagnosed low desire, yes, modestly: a 0.35-point improvement over placebo on a 1.2-to-6 desire scale across two Phase 3 trials.
Is PT-141 FDA approved?
Yes, as Vyleesi, since June 2019, for one indication in premenopausal women. Research-labelled PT-141 vials are not approved products.
What is the PT-141 dosage?
The approved dose is 1.75 mg injected at least 45 minutes before sex, no more than once in 24 hours and no more than eight times a month. No validated dose exists for men.
How long does PT-141 take to work?
The label says to inject at least 45 minutes before sexual activity. The early men's nasal-spray studies reported onset around 30 minutes.
Is PT-141 nasal spray the same as the injection?
No. No nasal spray is approved; those sold are compounded. The old men's trials used nasal doses of 7 mg and up, which do not translate to the 1.75 mg injection.
What are the side effects of PT-141?
Nausea (40% in trials), flushing, headache, vomiting, injection site reactions, a temporary rise in blood pressure after every dose, and skin darkening in about 1%.
Is PT-141 safe with high blood pressure?
No. The label contraindicates it in uncontrolled hypertension and known cardiovascular disease, and does not recommend it for anyone at high cardiovascular risk.
Can you take PT-141 with Viagra or Cialis?
No trial has tested the combination, and both affect blood pressure in different ways. That is a conversation for a prescriber, not a forum.
PT-141 vs kisspeptin: which is better?
They have never been compared. PT-141 is an approved drug with Phase 3 data in women; kisspeptin is an unapproved research peptide with small human studies and no approval anywhere.
Is it legal to buy PT-141 online?
Vyleesi and compounded bremelanotide are legal by prescription. The FDA considers research-labelled vials marketed for human use to be unapproved drugs, and it named PT-141 in four warning letters in August 2026.
Resources
Pfaus et al. (2022), CNS Spectrums, neurobiology of bremelanotide — https://pubmed.ncbi.nlm.nih.gov/33455598/
Kingsberg et al. (2019), Obstetrics and Gynecology, the two RECONNECT Phase 3 trials — https://pubmed.ncbi.nlm.nih.gov/31599840/
Simon et al. (2022), Journal of Women's Health, RECONNECT subgroup analyses — https://pubmed.ncbi.nlm.nih.gov/35230162/
Diamond et al. (2004), International Journal of Impotence Research, intranasal PT-141 in men — https://pubmed.ncbi.nlm.nih.gov/14963471/
Safarinejad and Hosseini (2008), Journal of Urology, sildenafil non-responders — https://pubmed.ncbi.nlm.nih.gov/18206919/
Journal of Urology (2023), expression of concern on Safarinejad and Hosseini (2008) — https://pubmed.ncbi.nlm.nih.gov/36626345/
Cosette Pharmaceuticals (2024), Vyleesi (bremelanotide) prescribing information, DailyMed — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
Sprout Pharmaceuticals, Addyi (flibanserin) prescribing information, DailyMed — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394
FDA (2018), guidance on compounded drugs that are essentially copies of approved products — https://www.fda.gov/media/98964/download
FDA (2026), Category 2 bulk drug substances list, melanotan II entry — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
FDA (2026), warning letter to TXP Innovations LLC (Tex Peptides), August 24 — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026
FDA (2026), warning letter to Royal Peptides LLC, August 24 — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026
FDA (2026), warning letter to Peptide Partners LLC, August 24 — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026
FDA (2026), warning letter to NuScience Peptides LLC, August 24 — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026
WADA (2026), Prohibited List — https://www.wada-ama.org/en/resources/2026-prohibited-list
ONPEPS, PT-141 library entry — https://www.onpeps.com/peptides/pt-141
